PHARMAC: Newly Funded Medicine To Benefit 110 More People With Thyroid, Liver, And Kidney Cancer Dr David Hughes, Pharmac’s ...

Pharmac is funding Lisdexamfetamine for ADHD and narcolepsy, benefiting more than 6000 people from December. Pharmac is ...

Pharmac has decided to fund an at-home low sensitivity test kit that confirms a pregnancy has ended following a medical abortion. The urine test kit (branded as CheckToP) detects the levels of ...

Pharmac is set to fund an at-home testing kit to find out if a pregnancy termination has been successful. The testing kit ...

Pharmac has decided to disestablish it's Māori advisory group. In a statement, the chairperson of the drug funding agency ...

Advocacy group Aroreretini Aotearoa, says the changes will improve productivity for the ADHD community, by almost 57-million-dollars. Chief medical officer David Hughes says it will streamline ...

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

By AUT Journalism Student Vivek Panchal The Government has announced it will increase funding for Pharmac, boosting ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...

It will be a relief for women dealing with years of shortages of oestrogen patches.